Lower limb muscle MRI fat fraction is a responsive outcome measure in CMT X1, 1B and 2A
© 2024 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association..
OBJECTIVE: With potential therapies for many forms of Charcot-Marie-Tooth disease (CMT), responsive outcome measures are urgently needed for clinical trials. Quantitative lower limb MRI demonstrated progressive calf intramuscular fat accumulation in the commonest form, CMT1A with large responsiveness. In this study, we evaluated the responsiveness and validity in the three other common forms, due to variants in GJB1 (CMTX1), MPZ (CMT1B) and MFN2 (CMT2A).
METHODS: 22 CMTX1, 21 CMT1B and 21 CMT2A patients and matched controls were assessed at a 1-year interval. Intramuscular fat fraction (FF) was evaluated using three-point Dixon MRI at thigh and calf level along with clinical measures including CMT examination score, clinical strength assessment, CMT-HI and plasma neurofilament light chain.
RESULTS: All patient groups had elevated muscle fat fraction at thigh and calf levels, with highest thigh FF and atrophy in CMT2A. There was moderate correlation between calf muscle FF and clinical measures (CMTESv2 rho = 0.405; p = 0.001, ankle MRC strength rho = -0.481; p < 0.001). Significant annualised progression in calf muscle FF was seen in all patient groups (CMTX1 2.0 ± 2.0%, p < 0.001, CMT1B 1.6 ± 2.1% p = 0.004 and CMT2A 1.6 ± 2.1% p = 0.002). Greatest increase was seen in patients with 10-70% FF at baseline (calf 2.7 ± 2.3%, p < 0.0001 and thigh 1.7 ± 2.1%, p = 0.01).
INTERPRETATION: Our results confirm that calf muscle FF is highly responsive over 12 months in three additional common forms of CMT which together with CMT1A account for 90% of genetically confirmed cases. Calf muscle MRI FF should be a valuable outcome measure in upcoming CMT clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Annals of clinical and translational neurology - 11(2024), 3 vom: 27. März, Seite 607-617 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Doherty, Carolynne M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 27.03.2024 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/acn3.51979 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366639056 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366639056 | ||
| 003 | DE-627 | ||
| 005 | 20240329000333.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/acn3.51979 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM366639056 | ||
| 035 | |a (NLM)38173284 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Doherty, Carolynne M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lower limb muscle MRI fat fraction is a responsive outcome measure in CMT X1, 1B and 2A |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2024 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. | ||
| 520 | |a OBJECTIVE: With potential therapies for many forms of Charcot-Marie-Tooth disease (CMT), responsive outcome measures are urgently needed for clinical trials. Quantitative lower limb MRI demonstrated progressive calf intramuscular fat accumulation in the commonest form, CMT1A with large responsiveness. In this study, we evaluated the responsiveness and validity in the three other common forms, due to variants in GJB1 (CMTX1), MPZ (CMT1B) and MFN2 (CMT2A) | ||
| 520 | |a METHODS: 22 CMTX1, 21 CMT1B and 21 CMT2A patients and matched controls were assessed at a 1-year interval. Intramuscular fat fraction (FF) was evaluated using three-point Dixon MRI at thigh and calf level along with clinical measures including CMT examination score, clinical strength assessment, CMT-HI and plasma neurofilament light chain | ||
| 520 | |a RESULTS: All patient groups had elevated muscle fat fraction at thigh and calf levels, with highest thigh FF and atrophy in CMT2A. There was moderate correlation between calf muscle FF and clinical measures (CMTESv2 rho = 0.405; p = 0.001, ankle MRC strength rho = -0.481; p < 0.001). Significant annualised progression in calf muscle FF was seen in all patient groups (CMTX1 2.0 ± 2.0%, p < 0.001, CMT1B 1.6 ± 2.1% p = 0.004 and CMT2A 1.6 ± 2.1% p = 0.002). Greatest increase was seen in patients with 10-70% FF at baseline (calf 2.7 ± 2.3%, p < 0.0001 and thigh 1.7 ± 2.1%, p = 0.01) | ||
| 520 | |a INTERPRETATION: Our results confirm that calf muscle FF is highly responsive over 12 months in three additional common forms of CMT which together with CMT1A account for 90% of genetically confirmed cases. Calf muscle MRI FF should be a valuable outcome measure in upcoming CMT clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Morrow, Jasper M |e verfasserin |4 aut | |
| 700 | 1 | |a Zuccarino, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Paige |e verfasserin |4 aut | |
| 700 | 1 | |a Wastling, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Pipis, Menelaos |e verfasserin |4 aut | |
| 700 | 1 | |a Zafeiropoulos, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Stephens, Katherine J |e verfasserin |4 aut | |
| 700 | 1 | |a Grider, Tiffany |e verfasserin |4 aut | |
| 700 | 1 | |a Feely, Shawna M E |e verfasserin |4 aut | |
| 700 | 1 | |a Nopoulous, Peggy |e verfasserin |4 aut | |
| 700 | 1 | |a Skorupinska, Mariola |e verfasserin |4 aut | |
| 700 | 1 | |a Milev, Evelin |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolaisen, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Dudzeic, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a McDowell, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Dilek, Nuran |e verfasserin |4 aut | |
| 700 | 1 | |a Muntoni, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Rossor, Alexander M |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Sachit |e verfasserin |4 aut | |
| 700 | 1 | |a Laura, Matilde |e verfasserin |4 aut | |
| 700 | 1 | |a Yousry, Tarek A |e verfasserin |4 aut | |
| 700 | 1 | |a Thedens, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Thornton, John |e verfasserin |4 aut | |
| 700 | 1 | |a Shy, Michael E |e verfasserin |4 aut | |
| 700 | 1 | |a Reilly, Mary M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of clinical and translational neurology |d 2014 |g 11(2024), 3 vom: 27. März, Seite 607-617 |w (DE-627)NLM234874031 |x 2328-9503 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:3 |g day:27 |g month:03 |g pages:607-617 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/acn3.51979 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 3 |b 27 |c 03 |h 607-617 | ||